Compare TG Therapeutics Inc (TGTX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Clear Secure Inc — how do they compare? TG Therapeutics Inc trades at $50 (market cap $7.64B), while Clear Secure Inc trades at $46.91 (market cap $4.98B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Clear Secure Inc pays a 1.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | YOU | |
|---|---|---|
Market Cap | $7.64B | $4.98B |
Sector | Health | Technology |
52-Week High | $59.06 | $62.36 |
52-Week Low | $26.94 | $29.61 |
Enterprise Value | $7.84B | $4.13B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
CLEAR Secure (YOU) trades at $46.16, down 9.86% in the past 24 hours, approaching key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating expectations at $0.49 per share versus $0.40 expected, driven by 66.66% gross margins and 90.29% ROE. Recent news highlights enterprise expansion including corporate membership launches and airport service investments.
Outlook remains positive with revenue growth accelerating to $1.0B in 2026 and analyst consensus leaning bullish (44% Buy ratings). Key risks include competitive pressure in identity verification and execution of new corporate initiatives. The current dip may present a buying opportunity for growth investors given strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
